Related Experiment Video
Updated: Aug 13, 2026
04:40
Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Antithrombotics in thrombosis and cancer
1Albany College of Pharmacy, 106 New Scotland Avenue Albany, NY 12208-3492, USA. mousas@acp.edu
Hamostaseologie
|January 6, 2006
Summary
Low molecular weight heparin (LMWH) and warfarin show promise in improving cancer patient survival by targeting thrombosis and tumor growth. These anticoagulants, along with antiplatelet drugs, may offer therapeutic benefits in cancer treatment.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Cancer patients often experience hypercoagulable states, increasing thrombosis risk due to cancer and treatments.
- Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) impact tumor growth and metastasis through various mechanisms.
- Clinical trials indicate LMWH and warfarin may improve survival in cancer patients with thromboembolic disorders.
Purpose of the Study:
- To investigate the role of anticoagulants and antiplatelet drugs in cancer therapy.
- To explore the mechanisms by which LMWH and warfarin affect tumor angiogenesis, growth, and metastasis.
- To assess the potential of modulating coagulation factors for cancer treatment.
Main Methods:
- Review of clinical trials and laboratory studies on heparin, warfarin, and antiplatelet drugs in cancer.
- Analysis of heparin's interaction with angiogenic factors (FGF2, VEGF) and coagulation components (tissue factor, TFPI).
- Evaluation of non-coagulant activities of anticoagulants in regulating tumor progression.
Main Results:
- LMWH and warfarin demonstrated a positive impact on cancer patient survival compared to UFH.
- Studies showed LMWH, warfarin, anti-VIIa, and TFPI play significant roles in regulating angiogenesis and metastasis.
- Modulation of tissue factor/VIIa non-coagulant activities may inhibit tumor-associated angiogenesis.
Conclusions:
- LMWH and warfarin show potential therapeutic benefits for cancer patients, particularly those with thrombosis.
- Targeting coagulation pathways with anticoagulants and antiplatelets may offer a novel approach to inhibit cancer growth and metastasis.
- Combination therapy with antiplatelets and anticoagulants could enhance benefits for cancer patients.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...